Chemotherapeutic approaches to advanced breast cancer.

abstract：:At Indiana University, we began clinical trials with ifosfamide in 1981. Although our initial efforts were in a variety of tumor types, including pancreatic cancer, we have most recently focused our attention on two tumors that have historically exhibited a higher degree of chemosensitivity--testicular cancer and smal...

journal_title：Seminars in oncology

authors： Loehrer PJ,Williams SD,Nichols CR,Einhorn LH

更新日期：1992-02-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) remains a malignancy that is refractory to most currently available chemotherapeutic agents. The most frequently used systemic therapy is cisplatin-based combination therapy, which is not always suitable for patients with stage IV disease because of toxicity. Thus, any single agent w...

journal_title：Seminars in oncology

authors： Manegold C

更新日期：1998-08-01 00:00:00

abstract：:Diffuse large B-cell lymphoma (DLCL) is the most frequently diagnosed subtype of non-Hodgkin's lymphoma (NHL), and more than 50% of cases present in patients over 60 years of age. Although cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) is currently regarded as the gold standard treatment for DLCL, less tha...

journal_title：Seminars in oncology

authors： Coiffier B

更新日期：2002-04-01 00:00:00

abstract：:A dose-finding study was set up to identify the optimal dose of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin for phase II studies in patients with advanced chemotherapy-naive non-small cell lung cancer (NSCLC). The influence of drug sequence on the toxicity and pha...

journal_title：Seminars in oncology

authors： Giaccone G,Huizing M,Postmus PE,ten Bokkel Huinink WW,Koolen M,van Zandwijk N,Vermorken JB,Beijnen JH,Dalesio O,Pinedo HM

更新日期：1995-08-01 00:00:00

abstract：:Photodynamic therapy (PDT) is a form of non-ionizing radiation therapy that uses a drug, called a photosensitizer, combined with light to produce singlet oxygen ((1)O2) that can exert anti-cancer activity through apoptotic, necrotic, or autophagic tumor cell death. PDT is increasingly being used to treat thoracic mali...

journal_title：Seminars in oncology

authors： Simone CB 2nd,Cengel KA

更新日期：2014-12-01 00:00:00

abstract：:Navelbine (NVB) or 5' nor-anhydro-vinblastine was shown to present a broader antitumor activity and to induce fewer side effects than vinblastine (VBL) or vincristine (VCR). The possible mechanisms of these differences were analyzed with in vitro methods. At substoichiometric concentrations, the three drugs inhibit mi...

journal_title：Seminars in oncology

authors： Fellous A,Ohayon R,Vacassin T,Binet S,Lataste H,Krikorian A,Couzinier JP,Meininger V

更新日期：1989-04-01 00:00:00

abstract：:High-dose interferon alfa (IFN alfa) therapy induces an overall response rate of 25% to 30% in unselected patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma. Up to 50% of patients with relatively preserved immune reactivity respond to treatment. However, when dosages of 20 x 10(6) units o...

journal_title：Seminars in oncology

authors： Krown SE

更新日期：1990-02-01 00:00:00

abstract：:A phase II study was conducted to evaluate the efficacy and toxicity of lomustine, cytarabine, mitoxantrone and prednisone (CAMP) chemotherapy in doxorubicin-resistant intermediate- and high-grade malignant non-Hodgkin's lymphomas (NHL). Among 30 patients, the complete remission rate was 27% (duration: 10, 16, 22, 35,...

journal_title：Seminars in oncology

authors： Ruit JB,Löwenberg B,Hagenbeek A,Verhoef GE,Wielenga JJ,Michiels J,Sizoo W

更新日期：1990-12-01 00:00:00

abstract：:Cisplatin is recognized as an active chemotherapeutic agent in a broad variety of human tumors. The severe emetic effects of cisplatin, however, result in both acute and delayed emesis syndromes causing considerable morbidity. Over the last decade, the standard of therapy for control of cisplatin-induced emesis has be...

journal_title：Seminars in oncology

authors： Perez EA,Hesketh PJ,Gandara DR

更新日期：1991-02-01 00:00:00

abstract：:Lymphoma and myeloma represent an increasingly important cause of morbidity and mortality in the older patient group. Studies to date, while limited, suggest that there may be differences in the underlying biology of the tumor cell of some lymphoid malignancies in younger versus older patients. Significant new data wi...

journal_title：Seminars in oncology

authors： Westin EH,Longo DL

更新日期：2004-04-01 00:00:00

abstract：:Carboplatin is one of the most active agents in untreated small cell lung cancer (SCLC) (11% complete response [CR], 59% CR plus partial response [PR]). Combination carboplatin/etoposide/vincristine (CEV) (phase II trial) led to an overall remission rate of 84% in patients with limited disease (LD), with 52% CRs. The ...

journal_title：Seminars in oncology

authors： Gatzemeier U,Hossfeld DK,Neuhauss R,Reck M,Achterrath W,Lenaz L

更新日期：1992-02-01 00:00:00

abstract：:Intraoperative lymphatic mapping and selective lymphadenectomy for solid malignancies is a novel technique, having been introduced into surgical practice in the last 12 years. Dissemination of this technique among surgeons has followed a course similar to that found with the introduction of new laparoscopic techniques...

journal_title：Seminars in oncology

authors： Wilke LG

更新日期：2004-06-01 00:00:00

abstract：:Cancer vaccines have shown success in curing tumors in preclinical models. Accumulating evidence also supports their ability to induce immune responses in patients. In many cases, these responses correlate with improved clinical outcomes. However, cancer vaccines have not yet demonstrated their true potential in clini...

journal_title：Seminars in oncology

authors： Keenan BP,Jaffee EM

更新日期：2012-06-01 00:00:00

abstract：:Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options and exceedingly high mortality rates. Currently, cure can only be achieved through resection, however the vast majority of patients present with advanced disease for which upfront surgery is not an option. In...

journal_title：Seminars in oncology

authors： Raufi AG,Manji GA,Chabot JA,Bates SE

更新日期：2019-02-01 00:00:00

abstract：:Tamoxifen has been demonstrated to be hepatocarcinogenic in some but not all strains of the laboratory rat and is not a carcinogen in the mouse. To resolve the question of whether tamoxifen is genotoxic in humans, many laboratories have studied its interspecies metabolism and its propensity to form DNA adducts. This r...

journal_title：Seminars in oncology

authors： Tannenbaum SR

更新日期：1997-02-01 00:00:00

abstract：:Most cellular proto-oncogenes encode proteins that participate in signaling pathways by which cells receive and execute instructions that lead to mitogenesis, differentiation, lineage determination, cell migration, extracellular matrix production, and apoptosis, among others. These proto-oncogene protein products incl...

journal_title：Seminars in oncology

authors： Arteaga CL,Khuri F,Krystal G,Sebti S

更新日期：2002-02-01 00:00:00

abstract：:Transport of folates and antifolates in most cells is mediated by the reduced folate carrier (RFCI), an anion exchanging concentrative process, which is opposed by independent exit pump(s) that are directly coupled to energy metabolism. The balance of these processes governs the free intracellular folate level that is...

journal_title：Seminars in oncology

authors： Sierra EE,Goldman ID

更新日期：1999-04-01 00:00:00

abstract：:Organ function preservation in patients with head and neck cancer can be achieved by intensity-modulated radiation therapy (IMRT). Much of the work on the physics of IMRT has been done for currently available IMRT systems. However, clinical data remain scarce. Before IMRT is accepted as a standard of care, more compre...

journal_title：Seminars in oncology

authors： Chao KS,Ozyigit G,Thorsdad WL

更新日期：2003-12-01 00:00:00

abstract：:Although originally developed as an antitumor agent in the 1970s, dexrazoxane (DEX) is currently used as a cardioprotective agent in combination with doxorubicin (DOX). Due to concerns about anthracycline-induced cardiotoxicity at higher cumulative doses, many investigators have chosen to administer DOX by prolonged i...

journal_title：Seminars in oncology

authors： Synold TW,Tetef ML,Doroshow JH

更新日期：1998-08-01 00:00:00

abstract：:Quality of life (QOL) variables are increasingly included as end points in cancer therapy trials, supplementing such traditional end points as survival time in evaluating the effects of cancer treatments. Consensus has been reached that a number of QOL components (symptom status and physical, emotional, role, and soci...

journal_title：Seminars in oncology

authors： Moinpour CM

更新日期：1994-10-01 00:00:00

abstract：:As continuous ambulatory peritoneal dialysis becomes more popular, the science of catheter selection, insertion, and maintenance becomes increasingly necessary. The proper use of and possible complications associated with several currently used catheters are discussed. The pros and cons of single- and double-cuff cath...

journal_title：Seminars in oncology

authors： Twardowski ZJ

更新日期：1985-09-01 00:00:00

abstract：:Immune dysregulation, a hallmark of chronic lymphocytic leukemia (CLL), manifests itself in three autoimmune diseases: warm autoimmune hemolytic anemia (AIHA); idiopathic thrombocytopenia (ITP); and, pure red cell aplasia (PRCA). AIHA occurs in 11% of advanced stage CLL patients. Prednisone is the first treatment of c...

journal_title：Seminars in oncology

authors： Diehl LF,Ketchum LH

更新日期：1998-02-01 00:00:00

abstract：:The combination of gemcitabine and docetaxel exhibits good activity in the treatment of advanced breast cancer. Phase II trial response rates using 21- or 28-day schedules have ranged from 36% to 79% in patient populations with varying degrees of pretreatment. In studies of extensively pretreated anthracycline-resista...

journal_title：Seminars in oncology

authors： Fumoleau P

更新日期：2003-04-01 00:00:00

abstract：:Cisplatin has been employed in the treatment of non-small-cell lung cancer (NSCLC) since the late 1970s. Current evidence suggests that it may be the most effective single drug for the treatment of NSCLC patients. The overall response rate as a single agent is 21%, though responses are higher in previously untreated p...

journal_title：Seminars in oncology

authors： Bunn PA Jr

更新日期：1989-08-01 00:00:00

abstract：:A phase I/II study was conducted to determine the response rate and the toxicity of escalating doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin with granulocyte colony-stimulating factor support in patients with untreated advanced head and neck carcinoma. Twenty-eight patients wi...

journal_title：Seminars in oncology

authors： Hitt R,Paz-Ares L,Hidalgo M,Colomer R,Brandariz A,Peña M,Alvarez-Vicent J,Hornedo J,Cortés-Funes H

更新日期：1997-12-01 00:00:00

abstract：:The targeting of molecular abnormalities in neoplasms may provide an opportunity to improve the selectivity of cancer therapy. Ras mutations are a common genetic event in human cancers. Other genetic changes in tumors can signal through ras-dependent pathways as well. The targeting of ras through the inhibition of Ras...

journal_title：Seminars in oncology

authors： Hahn SM,Bernhard E,McKenna WG

更新日期：2001-10-01 00:00:00

abstract：:Lung cancer is the number one cause of cancer-related death in both men and women in the United States. Non-small cell lung cancer accounts for approximately 85% of these cases. Despite complete resection, long-term survival for patients with operable disease remains poor. Studies exploring postoperative chemotherapy ...

journal_title：Seminars in oncology

authors： Pisters KM

更新日期：2001-08-01 00:00:00

abstract：:In the United States there are approximately 100,000 women living with metastatic breast cancer. Bone is the most common site of breast cancer metastases and it is estimated that up to 85% of patients dying from this disease have developed osseous involvement. Skeletal metastases are often associated with dangerous an...

journal_title：Seminars in oncology

authors： Van Poznak C

更新日期：2001-08-01 00:00:00

abstract：:Postmenopausal patients with advanced measurable and/or evaluable breast cancer entered a phase II trial of multiple agent cytotoxic therapy combined with endocrine therapy. Cycles of PNMF (prednimustine, novantrone, methotrexate, and 5-fluorouracil) were repeated every 4 weeks as follows: P, 100 mg/m2 PO on days 1 to...

journal_title：Seminars in oncology

authors： Mouridsen HT,Andersson M,Pedersen L

更新日期：1986-03-01 00:00:00

abstract：:Radiation is an effective modality to aid in symptom management of patients with metastatic disease. The type and duration of treatment depends on the Karnofsky performance status (KPS) of the patient and type and status of the cancer. Abbreviated treatment regimens may be favored in this patient population. They prov...

journal_title：Seminars in oncology

authors： Konski A,Feigenberg S,Chow E

更新日期：2005-04-01 00:00:00